Anti-Carbamylated Protein Antibodies in a Sample of Iraqi Patients with Systemic Lupus Erythematosus

Sedeeq, Hanan Mazin; Jassim, Nizar Abdulateef; Mustafa Kamil, Leen Khalooq

doi:10.52573/ipmj.2025.146212

Journals List

Anti-Carbamylated Protein Antibodies in a Sample of Iraqi Patients with Systemic Lupus Erythematosus

Iraqi Postgraduate Medical Journal

Article 3, Volume 24, Issue 2, April 2025, Pages 167-172 PDF (534.11 K)

Document Type: Research Paper

DOI: 10.52573/ipmj.2025.146212

Authors

Hanan Mazin Sedeeq^* ¹; Nizar Abdulateef Jassim²; Leen Khalooq Mustafa Kamil³

¹Nineveh college of medicine

²department of medicine/Baghdad university

³immunology , national center for teaching laboratories / baghdad-iraq

Abstract

ABSTRACT
Background:: Systmic lupus erythematosus is an autoimmune illness characterized by extensive immune complex deposition and consequent tissue damage. It is distinguished by the presence of antinuclear antibodies and the involvement of several organ systems.
Objective: is to assess serum anticarbamylated protein antibody (anti-CarP) level in SLE patients and evaluate the association between anti-CarP antibodies with different disease characteristics.
Subjects and Methods: Serum level of anti-CarP antibody was measured for a total of 40 adult female patients with SLE whom attended the Rheumatology Consultation Clinic of Baghdad Teaching Hospital / Medical City, compared with 40 apparently healthy controls matched in ages and sexes to the patients using Enzyme Linked Immuno-Sorbent Assay (ELISA) technique which is also used to measure serum anti ds-DNA levels.
Results: Serological data showed that the serum level of anti-CarP antibody was significantly higher in the SLE patients compared with controls p value (0.001). In SLE patients there was a significant correlation between anti-CarP antibody and both body mass index and serum ds-DNA antibody levels, however, did not correlate with SLEDAI score.
Conclusion: Serum anti-Carp antibody level was able to differentiate between patient with SLE and healthy control with sensitivity 80% , specificity 77.50% and accuracy 78%.

Keywords

SLE; anti-CarP; ELISA; ds-DNA; SLEDAI

References

Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol. 2016;28:497-505.
Mydel P, Wang Z, Brisslert M, Hellvard A, Dahlberg LE, Hazen SL, et al. Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. The Journal of Immunology. 2010;184:6882-90.
Li Y, Jia R, Liu Y, Tang S, Ma X, Shi L, et al. Antibodies

against carbamylated vimentin exist in systemic lupus erythematosus and correlate with disease activity. Lupus. 2020;29:239-47.

Li YN, Xiang XH, Zhao J, Li Y, Sun F, Wang HY, et al. Significance of anti-carbamylated fibrinogen antibodies in systemic lupus erythematosus. Beijing da xue xue bao. Yi xue ban= Journal of Peking University. Health Sciences. 2019;51:1019-24.
Dua’a Akram AL, Hasan BF, AL-Hafidh AH. Estimation of Some Immunological and Biochemical in the Patients with Systemic Lupus Erythematosus in Males and Females in Baghdad. Med Leg Updat. 2020;20:972–78.
Al Hasso I, Al-Derzi A, Abbas A, Isho F, Alnuimi A. Role of microRNAs in SLE The role of microRNAs (MiR-125a and MiR-146a), RANTES, and and IFN-yin systemic lupus erythematosus, Ann Trop Med & Public Health. 2020;23(S13B):DOI: http://doi.org/10.36295/ASRO.2020.231382.
Adwan M. Clinical and serologic characteristics of systemic lupus erythematosus in the arab world: a pooled analysis of 3,273 patients. Arch Rheumatol. 2018;33(4):455-63.
Nightingale AL, Davidson JE, Molta CT, et al . Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. Lupus Sci Med. 2017;4: e000172.

9. Al-Husseini RMA-H. The association between genetic polymorphisms of Il-6 gene and susceptibility of systemic lupus erythematosus in Iraqi population. Eurasian J Biosci. 2020;14:2559–67.

10. Kaul, A., Gordon, C., Crow, M. et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2(1): https://doi.org/10.1038/nrdp.2016.39.

11. Tedeschi SK, Barbhaiya M, Malspeis S, Lu B, Sparks JA, Karlson EW, et al. Obesity and the risk of systemic lupus erythematosus among women in the Nurses’ Health Studies. InSeminars in arthritis and rheumatism 2017; 47:376-83. WB Saunders.

12. Elsayed SA, Kamaly HM, Esmail MA. Co-positivity of anti-dsDNA, anti-nucleosome, and anti-smith autoantibodies as serological biomarkers for disease activity in systemic lupus erythematosus. Egyptian Rheumatology and Rehabilitation. 2022;49:1-8.A.

13. Shang X, Ren L, Sun G, Yu T, Yao Y, Wang L, et al. Anti‐dsDNA, anti‐nucleosome, anti‐C1q, and anti‐histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity. Immunity, Inflammation and Disease. 2021;9:407-18.

14. Özdemir B, Erden A, Erten Ş, Yeşil TH, Alışık M, Kucuksahin O. Can anticarbamylated protein antibodies be used to support the diagnosis of systemic lupus erythematosus?. Biomarkers in Medicine. 2021;15:1253-60.

15. Massaro L, Ceccarelli F, Colasanti T, Pendolino M, Perricone C, Cipriano E, et al. Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement. Lupus. 2018 ;27:105-11.

Statistics

Article View: 386

PDF Download: 115